King's Research Portal

DOI:

[10.1016/j.mce.2016.07.014](https://doi.org/10.1016/j.mce.2016.07.014)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Pingitore, A., Caroleo, M. C., Cione, E., Castañera Gonzalez, R., Huang, G. C., & Persaud, S. (2016). Fine tuning of insulin secretion by release of nerve growth factor from mouse and human islet -cells. *Molecular and Cellular Endocrinology*, 436, 23-32. <https://doi.org/10.1016/j.mce.2016.07.014>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Fine tuning of insulin secretion by release of nerve growth factor from mouse and human islet β -cells

Attilio Pingitore¹, Maria Cristina Caroleo², Erika Cione², Ramon Castañera Gonzalez³, Guo Cai Huang¹, Shanta Persaud^{1,4}

¹Diabetes Research Group, Diabetes & Nutritional Sciences Division, King's College London, Guy's Campus, SE1 1UL, London United Kingdom

²Department of Pharmacy, Nutritional and Health Sciences, University of Calabria, Via Savinio, 87036 Rende, Italy

³Department of General Surgery, Rio Carrión Hospital, University Hospital Complex of Palencia, 34005, Palencia, Spain,

⁴corresponding author. Prof. Shanta Persaud, shanta.persaud@kcl.ac.uk, Tel: +44-20 7848 6275 Fax: +44-20 7848 6280

Abstract

Nerve growth factor (NGF) is a protein required for neuronal development that also has regulatory functions in non-neuronal cells. Both NGF and its membrane receptors trkA and p75 are expressed by islet β -cells. In this study we dynamically profiled NGF secretion from islets and used selective trkA and p75 inhibitors to identify the role of endogenous NGF in β -cell stimulus-secretion coupling. NGF secretion from mouse islets was transient and did not accompany the sustained second phase of glucose-induced insulin secretion. Despite being present in human islets, NGF was not released at sufficient levels to be quantified. Inhibition of NGF signaling through trkA and p75^{NTR} increased basal insulin secretion from both human and mouse islets, but impaired glucose-stimulated insulin secretion. These data support a role for islet NGF in fine-tuning insulin secretion, to both maintain a low basal level of insulin output and contribute to the biphasic secretory response to glucose.

Highlights

- Glucose stimulates transient NGF secretion from mouse islets
- Disruption of NGF signaling via trk A and p75^{NTR} increases basal insulin secretion
- Inhibition of trkA and p75^{NTR} impairs glucose-induced insulin secretion
- p75^{NTR} binds to β -cell Rho-GDI, which may modulate the amplitude of insulin release

Keywords

NGF, insulin secretion, islets of Langerhans, β -cells, trkA, p75^{NTR}

Abbreviations

BMI, body mass index ; ECL, enhanced chemoluminescence; GDI, GDP-dissociation inhibitor; glucose-stimulated insulin secretion, glucose-stimulated insulin secretion; GTP, guanosine tri-phosphate; HRP, horseradish peroxidase; ICD, intracellular domain; NGF, nerve growth factor; PAGE, polyacrylamide gel electrophoresis; PKC, protein kinase C; PMA, 4 β -phorbol-12-myristate-13-acetate; Rho-GDI, Rho GDP dissociation inhibitor; SDS, sodium dodecyl sulfate; TNF, tumour necrosis factor

1. INTRODUCTION

In addition to insulin, the main regulator of glucose homeostasis, islet β -cells are capable of storing a wide array of peptides and small molecules within their secretory vesicles (Suckale and Solimena, 2010), many of which can act locally at β -cell receptors to exert autocrine and paracrine effects (Amisten et al., 2013). Nerve growth factor (NGF) is one of those peptides that is synthesised and secreted by β -cells in response to appropriate stimuli (Rosenbaum et al., 1998). This peptide was originally identified as a factor necessary for correct neuronal growth and differentiation (Cohen and Montalcini, 1957) and it has since been demonstrated to control a broader range of homeostatic responses both in the central and peripheral nervous systems, as well as in non-neuronal tissues (Kaplan and Miller, 1997).

NGF acts *via* two membrane receptors: the low affinity $p75^{\text{NTR}}$, an atypical member of the TNF α superfamily (Zampieri and Chao, 2006), and the high affinity $trkA$, belonging to the tyrosine kinase receptor family (Muragaki et al., 1995). While $trkA$ works through phosphorylation, mainly regulating the activation of signals promoting cell survival, proliferation and differentiation (Freund and Frossard, 2004), $p75^{\text{NTR}}$ does not possess catalytic activity but it recruits intracellular effectors depending on its *holo*- (NGF-bound) and *apo*- (unbound) forms (Roux and Barker, 2002). In those systems expressing both receptors, $p75^{\text{NTR}}$ can co-operate with $trkA$ forming a “super affinity” receptor, thus enhancing the response to low concentrations of NGF (Huber and Chao, 1995).

In addition to expressing NGF, islets also express both $trkA$ and $p75^{\text{NTR}}$, which are localised to β -cells (Vidaltamayo et al. 2003). Identification of NGF and its receptors within islets led to investigations on the existence of a possible autocrine loop, which indicated that NGF is released from rat islets in a glucose-dependent manner, up-regulates β -cell $trkA$ expression (Rosenbaum et al., 1998), and plays a role in β -cell survival via $trkA$ (Pierucci et al., 1991). It has been reported that individuals with type 2 diabetes possess elevated levels of circulating NGF (Kim et al., 2009) and streptozotocin-induced damage of β -cells *in vivo* and *in vitro* results in up-regulation of NGF secretion (Larrieta et al., 2006). These observations, together with the insulin secretagogue effects of NGF (Rosenbaum et al., 2001), suggest that increased local NGF levels following β -cell damage may be responsible for promoting cell survival and enhancing their insulin secretory capacity.

These earlier islet studies have mainly focused on the action of NGF signaling via $trkA$ in static incubation experiments, and there is currently insufficient information available on the role of NGF in dynamic insulin secretion and on its signaling in islets via the less well studied $p75^{\text{NTR}}$. In the current study we have therefore used selective inhibitors of NGF action at both $trkA$ and $p75^{\text{NTR}}$ in dynamic perfusion experiments with isolated mouse and human islets to provide new insights into the autocrine/paracrine loop signaling elicited by islet-derived NGF.

2. METHODS

2.1 Materials

Culture media, supplements and NGF (Sigma-Aldrich, UK; anti-NGF neutralising antibody (Alomone labs, Israel); Ro 08-2750 (Tocris, UK); TAT-PEP5 (Calbiochem, UK); RIPA buffer, PureProteome Protein G Magnetic Beads and Amicon Ultracel 3K centrifugal filters (Millipore, UK); protease and phosphatase inhibitor cocktail (Roche, UK); 5% fat-free milk solution (Applichem, UK); rabbit-anti-NGF, rabbit-anti- $p75^{\text{NTR}}$, rabbit-anti-RhoGDI antibodies, X-ray films (Santa Cruz Biotechnologies, USA); guinea pig-anti-insulin antibody and aqueous mounting media (Dako, UK); Alexa-fluor donkey-anti-rabbit 488-conjugated IgG, donkey-anti-guinea pig 594-conjugated IgG and 10% polyacrylamide gels (Life Sciences, UK); donkey-anti-rabbit HRP-conjugated IgG, ECL substrate, NGF E-max ELISA kit and RealTime-Glo™ Viability Assay (Promega, UK); BCA kit (Pierce, UK).

2.2 Mouse and human islets

Mouse islets were isolated from male ICR mice (20-25g) by collagenase digestion (Papadimitriou et al., 2007) and human islets were isolated from eleven non-diabetic donors (BMI: 29.9 ± 1.5 ; donor age: 49 ± 3 years; 5M, 6F) at the King's College Hospital Islet Transplantation Unit, with appropriate ethical approval (Huang et al., 2004). Islets were maintained at 37°C in RPMI supplemented with 10% fetal bovine serum, 2mM glutamine and 100U/ml/0.1mg/ml penicillin/streptomycin (mouse) or CMRL supplemented with 2% human albumin, 4mM glutamine, 2mM HEPES (pH 7.2-7.4), and 10mM nicotinamide (human).

2.3 MIN6 cells and pseudoislets

MIN6 β -cells were maintained (37°C, 5% CO₂) in DMEM supplemented with 10% fetal bovine serum, 2mM glutamine and 100U/ml/0.1mg/ml penicillin/streptomycin. For some experiments pseudoislets were generated by culturing MIN6 cells for 7 days, essentially as described (Hauge-Evan et al., 1999), although uncharged Petri dishes were used rather than gelatin-coated ones.

2.4 Immunofluorescent detection of NGF

Non-pathological human pancreas samples were embedded into paraffin blocks and 5 μ m sections were boiled in 0.01M citric acid buffer (pH 6.0) for 2.5 minutes for antigen retrieval. Sections were blocked (0.1% donkey serum in PBS with 0.02% triton X-100, 1h, room temperature), incubated at 4°C overnight with rabbit anti-NGF (1:50) and guinea pig anti-insulin (1:200) then exposed to Alexa-fluor secondary antibodies (1:250) for 1h at room temperature. Nuclei were stained with DAPI and images were acquired using a Nikon eclipse TE2000-U microscope.

2.5 Static insulin secretion

Isolated islets were pre-incubated for two hours at 37°C in a saline buffer (Gey and Gey, 1936) containing 2mM glucose then groups of 3 islets (mouse), 5 islets (human) or 10 MIN6 pseudoislets were incubated in 250 μ L of medium supplemented with agents of interest for 1 hour, after which 200 μ L of supernatant was retrieved for assay of insulin content (Jones et al., 1988). When the anti-NGF neutralising antibody (AbNGF; 5 μ g/mL) or Ro 08-2750 (0.5 μ M or 10 μ M) were used, they were added during both the pre-incubation and incubation phases (Niederhauser et al., 2000; Caroleo et al., 2015).

2.6 Dynamic insulin secretion

Groups of 40 isolated mouse or 50 human islets were transferred to chambers containing 1 μ m pore-size nylon filters and perfused at a flow rate of 0.5ml/min at 37°C with a physiological salt solution (Gey and Gey, 1936) supplemented with agents of interest, essentially as described previously (Liu et al., 2009). When TAT-PeP5 was used, islets were pre-incubated for 20 minutes with 10 μ M before being transferred to the perfusion chambers. Perfusate samples were collected at 2-minute intervals and secreted insulin was measured by radioimmunoassay (Jones et al., 1988).

2.7 NGF secretion profiling

Groups of 200 isolated mouse or human islets were perfused, as described in section 2.6, initially with a salt solution supplemented with 2mM glucose, then with 20mM glucose for 20 minutes followed by a further 20 minutes with 20mM glucose in the presence of 500nM PMA, a PKC activator (Jones et al., 1989). Perfusates were collected every two

minutes on ice, and 10µL of each sample was used to profile insulin secretion. The remaining perfusates were concentrated by lyophilisation (mouse: 2-fold) or using Amicon 3K centrifugal filters (human: 10-fold) and NGF content was quantified with the NGF E-max ELISA kit, according to the manufacturer's instructions.

2.8 Real time monitoring of islet viability

The viability of mouse islets in culture following TAT-PeP5 treatment was evaluated using a realtime viability assay over 24h, according to the manufacturer's continuous monitoring protocol.

2.9 Immunoprecipitation of Rho-GDI

PureProteome Protein G magnetic beads were loaded with 2.5µg anti Rho-GDI primary antibody to immunoprecipitate Rho-GDI from 100µL of total MIN6 cell lysates. Proteins were fractionated by denaturing SDS polyacrylamide gel electrophoresis (10% gel, 45 minutes, 200V) (Carito et al. 2012), transferred onto 0.2µm pore nitrocellulose and probed overnight at room temperature with rabbit anti-p75^{NTR} antibody (1:500) and rabbit anti-Rho-GDI antibody (1:500). The membrane was then incubated for 1h at room temperature with anti-rabbit HRP-conjugated secondary antibody (1:10,000) and exposed to X-ray film after addition of the ECL substrate.

2.10 Statistical analyses

Data are expressed as mean±SEM. The numbers of experiments and replicates are included in the figure legends. Statistical analyses were performed by Student's *t-tests* and differences were considered significant for p values <0.05.

3. RESULTS

3.1 NGF is secreted from islets but does not follow a biphasic profile

Dynamic perfusion of isolated mouse islets at 2mM glucose indicated that there is a basal release of NGF and insulin, with NGF being secreted at a rate of 3.5-5 fg islet⁻¹ min⁻¹ and insulin at 1-2 pg islet⁻¹ min⁻¹. It can be seen from Figure 1a that during the first 10 minutes of exposure to 20mM glucose, there was a 6-8 fold rise in insulin output, which was accompanied by a 5-7 fold parallel increase in NGF secretion (t₁₀-t₂₀). Continued exposure to 20mM glucose (t₂₀-t₃₀) resulted in a sustained second phase of insulin secretion (approximately 4-5 fold basal), but NGF output declined towards basal levels. Exposure to the PKC activator PMA (t₃₀-t₅₀), triggered a rapid and sustained potentiation of glucose-stimulated insulin secretion, as expected (Jones et al., 1988), but it failed to produce a similar sustained increase in NGF secretion, despite two secretory peaks at t₃₄ and t₄₂. Perfusion experiments were also performed using isolated human islets, but although insulin secretion in response to glucose and PMA was readily detectable (data not shown), the amount of NGF released remained below the detection limit of the ELISA kit for every batch of human islets assayed (n=6). This inability to detect NGF secretion was not a consequence of the absence of this peptide in human islets since immunofluorescence staining of human pancreas indicated NGF expression by islets, where it co-localised with insulin immunoreactivity (Figure 1b).

3.2 Disruption of NGF signaling stimulates basal insulin release in static incubations.

Identification of dynamic basal and glucose-stimulated NGF secretion from islets (Figure 1a) led us to initially perform static incubation studies to determine the contribution of NGF released from islets under non-stimulatory conditions (2mM glucose) to insulin secretion. In these experiments the biological activity of endogenously released NGF was neutralised with an anti-NGF antibody (AbNGF, 5µg/mL), while the ability of endogenous NGF to bind to its

receptors was impaired by supplementing the incubation medium with Ro 08-2750 (Ro) at 0.5 and 10 μ M to disrupt binding to p75^{NTR} and both trkA and p75^{NTR}, respectively (Niederhauser et al., 2000). As shown in Figure 2a, mouse islets responded to NGF neutralisation by significantly increasing insulin secretion at 2mM glucose, and similar effects were observed following disruption of NGF binding to its receptors. Although we could not detect NGF secretion from human islets in perfusion experiments, a role for endogenous NGF in regulating insulin secretion was evident from the capacity of AbNGF and Ro to stimulate insulin secretion at 2mM glucose (Figure 2b), in a similar manner to that seen in mouse islets (Figure 2a). We confirmed that the increased insulin secretion observed with AbNGF was a direct consequence of changes in the secretory response of β -cells rather than via paracrine signaling of endogenous NGF through α - and/or δ -cells since MIN6 pseudoislets, which are composed entirely of β -cells, also responded with elevated insulin secretion when incubated with AbNGF at 2mM glucose (Figure 2c). The effects observed using AbNGF were dependent on neutralisation of endogenous NGF as exposure to 5 μ g/mL isotypic IgG rather than AbNGF did not induce any changes in insulin secretion from either mouse or human islets (Figure 2d).

3.3 Blockade of NGF signaling stimulates dynamic basal insulin release and reduces glucose-stimulated insulin secretion.

The data shown in Figures 2a and 2b are indicative of a negative feedback effect of locally released NGF on basal insulin secretion, which is not further modified by the addition of 50ng/mL exogenous NGF. The potential role of NGF in regulating the capacity of islets to show appropriate insulin secretion in response to a maximal stimulatory concentration of glucose (20mM), and further investigation of dynamic effects at 2mM glucose, were investigated using the multichannel perfusion system that we had used for quantification of NGF release since this represents an ideal approach for evaluation of the onset, amplitude and reversibility of insulin secretory responses. Perfusion of mouse islets with 0.5 μ M Ro, to block interaction of endogenous NGF with p75^{NTR} (Figure 3a), or 10 μ M Ro, to inhibit endogenous NGF binding to both trkA and p75^{NTR} (Figure 3b) resulted in significant elevation of basal insulin secretion, confirming the data obtained in the static incubation experiments (Figure 1a). Exposure of islets to 0.5 μ M Ro in the presence of 20mM glucose resulted in an insulin secretory profile virtually superimposable with that seen when islets were perfused with medium containing 20mM glucose alone (Figure 3a). However, it can be seen from Figure 3b that inhibition of p75^{NTR} and trkA with 10 μ M Ro caused a significantly delayed onset of glucose-stimulated insulin secretion, with a peak response 20 minutes after the increase in glucose concentration, rather than the immediate increase seen in the presence of 20mM glucose alone. In contrast, perfusion of islets at 20mM glucose in the presence of exogenous NGF (50ng/mL) did not affect the rate of onset of insulin secretion, but islets showed a significantly higher amplitude of insulin release than those perfused in the absence of NGF (Figure 3c). This was most apparent during the last 10 minutes of exposure to NGF (t_{40} - t_{50}), a time course over which the concentration of endogenously secreted NGF physiologically declined, according to the profile shown in Figure 1a.

The increase in basal insulin release upon inhibition of endogenous NGF action was confirmed in separate protocols where islets were perfused in the presence of 0.5 μ M or 10 μ M Ro (Figure 4a), and the elevation in secretion at 2mM glucose was transient and rapidly reversible upon withdrawal of the inhibitor. A role for basal NGF secretion in determining the rate of onset and amplitude of the insulin secretory response to 20mM glucose also emerges from the data in Figure 4b: when mouse islets were pre-exposed to 10 μ M Ro in the presence of 2mM glucose for the last 10 minutes of the pre-perfusion, the subsequent glucose-stimulated insulin secretion was impaired such that there was a delay in the first phase, even though the inhibitor was not present during the glucose challenge.

3.4 Disruption of p75^{NTR} activity impairs glucose-stimulated insulin secretion.

Given that p75^{NTR} is able to signal differently depending to whether it is bound or not to NGF (in its *holo*- or *apo*-forms) (Roux and Barker, 2002), further perfusion experiments were performed using the p75^{NTR}-selective inhibitor TAT-PeP5, which binds covalently to the intracellular domain (ICD) of the receptor (Yamashita and Tohyama, 2003), thus blocking its activity regardless of the presence of NGF. Treatment with TAT-PeP5 for 20 minutes prior to perfusion induced significant reductions in glucose-dependent insulin secretion from mouse (Figure 5a) and human (Figure 5b) islets. This inhibition was not due to TAT-PeP5 exerting deleterious effects on islet survival since continuous monitoring of islet viability for 24 hours after TAT-PeP5 exposure indicated that there was no difference compared to the profile obtained with control islets that had not been incubated with TAT-PeP5 (Figure 5c). In these experiments the reductions in glucose-stimulated insulin secretion in response to TAT-PeP5 treatment were similar in mouse and human islets, but there were differential effects on basal insulin secretion at 2mM glucose. Thus, as shown in Figure 5a and 5b, basal insulin release from TAT-PeP5-treated mouse islets was significantly higher than control, but it was not significantly different in human islets ($p>0.2$, AUC measurements of TAT-PeP5-treated vs control), perhaps a consequence of the higher basal secretion rate observed in the human islets.

3.5 p75^{NTR} interacts with Rho-GDI in β -cells.

p75^{NTR} does not directly regulate intracellular enzyme activity, but it interacts with intracellular proteins such as Rho-GDI, an inhibitor of Rho family GTPases, to influence cytosolic dynamics in a tissue-specific manner (Caroleo et al, 2015; Yamashita and Tohyama, 2003; Sachs et al, 2007; Deponi et al., 2009; Bilderback et al, 1999; Nevins and Turmon, 2006; Kowluru and Veluthakal, 2005). Rho-GDI has been implicated in insulin granule movement (Rorsman and Renström, 2003), and immunoprecipitation of this 21kDa protein in MIN6 β -cells followed by western blotting indicated that the low affinity 75kDa NGF receptor can interact directly with Rho-GDI (Figure 6).

4. DISCUSSION

It has been known for some time that rodent islet β -cells secrete NGF upon appropriate secretagogue stimulation (Rosebaum et al., 1998), but earlier experiments did not provide information on the time-course of NGF secretion, nor whether its release coincided with that of insulin. The dynamic perfusion studies presented here have demonstrated concomitant NGF and insulin secretion from mouse islets during the first 10 minutes of a glucose challenge, suggesting that release of NGF-containing granules occurs together with readily releasable insulin secretory granules during the first phase of secretion (Rorsman and Renström, 2003). Continued exposure to 20mM glucose induces insulin granule movement towards the plasma membrane, but under these circumstances of the slower, more sustained insulin secretory output NGF release from perfused mouse islets declined. We used the phorbol ester PMA to promote robust potentiation of glucose-stimulated insulin secretion and this provided further evidence of uncoupling of insulin and NGF secretion, similar to a previous observation in static incubation of rat islet cells where stimulation with the insulin secretagogue dbcAMP failed to increase NGF (Rosenbaum et al., 1998).

In contrast to our observations with mouse islets, we were unable to profile dynamic NGF secretion from human islets, as the amount of NGF released under all conditions was below the immunoassay detection limit of 7.8pg/mL, even when perfusates were concentrated 10-fold. However, immunohistochemical staining of human pancreas indicated that NGF was present in the insulin-containing cells and the increase in insulin secretion from human islets in response to a neutralising NGF antibody are consistent with NGF being secreted from human islets to have autocrine effects. Thus, it

1 is likely that NGF is released at lower levels in human islets than in mouse islets such that it does not reach sufficient
2 concentrations in the perfusate, even when concentrated, for reliable detection by ELISA.

3 NGF release from mouse islets accompanied basal insulin secretion at 2mM glucose and also during the first
4 phase of glucose-stimulated insulin secretion, and neutralisation of endogenous NGF elevated basal insulin secretion from
5 both mouse and human islets. These observations are consistent with islet-derived NGF contributing to the basal insulin
6 secretion tone, but our data indicating that inhibition of endogenous NGF signaling reduced glucose-stimulated insulin
7 secretion suggests that the NGF autocrine loop operates differentially at basal glucose and after islets are stimulated by
8 elevations in glucose concentration. This difference might be reflected in the roles of the two receptors in mediating the
9 effects of NGF, and the use of Ro to selectively inhibit NGF interaction with the high (trkA) and low (p75^{NTR}) affinity
10 receptors allowed us to investigate the contribution of these receptors to basal and glucose-stimulated insulin secretion.

11 Dynamic assessment of insulin secretion using Ro confirmed the inhibitory role played by endogenous NGF on
12 insulin secretion at 2mM glucose, and these experiments also demonstrated impairment of glucose-stimulated insulin
13 secretion upon perturbation of NGF signaling. In particular, the use of 10μM Ro to block NGF binding to both receptors
14 (Niederhauser et al., 2000) delayed the insulin secretory response to glucose such that the rapid first phase was lost. In
15 contrast, exogenous NGF potentiated glucose-stimulated insulin secretion, suggesting that the transient elevation of
16 endogenous NGF may have a physiological role to prevent hyperglycaemia. Indeed, it has been reported that an increase
17 in circulating NGF occurs during type 2 diabetes (Kim et al., 2009), which may be a compensatory mechanism to maintain
18 normoglycaemia. These results are also in agreement with an earlier report that acute and 5 days stimulation with NGF
19 increased insulin secretion from rat β-cells (Rosenbaum et al., 2001). However, continuous stimulation of β-cells with
20 high circulating levels of NGF coupled to a higher than normal glucose concentration could be a pathological mechanism
21 driving the loss of β-cell secretory capability in the longer term.

22 Thus, our data are consistent with NGF not only contributing to the maintenance of low levels of insulin release
23 in the absence of a glucose stimulus, but also being involved in the fine tuning of the glucose-dependent insulin secretory
24 response. In addition, basal NGF secretion from islets also contributes to the amplitude of first phase insulin secretion *per*
25 *se* since interfering with its binding to trkA and/or p75^{NTR} through pre-exposure of islets to Ro reduced their glucose-
26 stimulated insulin output. These direct, rapid effects of signaling via NGF receptors in islets to promote glucose-induced
27 insulin secretion are complementary to the long-term effects of NGF to up-regulate mRNA encoding voltage-gated
28 sodium channels in rat β-cells and increase β-cell electrical activity (Vidaltamayo et al., 2002), and its ability to increase
29 current through L-type Ca²⁺ channels in β-cells (Rosenbaum et al., 2002).

30 The majority of NGF-related islet studies published so far have focused on the long-term effects of NGF
31 signaling via trkA, and they were aimed at identifying its role in β-cell survival and proliferation (Rosenbaum et al., 1998;
32 Vidaltamayo et al., 2003; Pierucci et al., 1991; Hata et al., 2015). The low affinity receptor, p75^{NTR}, has been implicated
33 in regulating neuronal apoptosis and regeneration (Taborsky et al., 2014), control of glucose homeostasis via effects on
34 skeletal muscle (Baeza-Raja et al., 2005) and in mediating islet responses to the GLP-1 analogue exendin-4 (Gezginci-
35 Oktayoglu and Bolkent, 2009), and regulating cAMP levels independently of NGF (Baeza-Raja et al., 2016). In terms of
36 receptor actions, p75^{NTR} recruits effectors via its intracellular C-terminal domain (ICD) and a role for its correct cycling
37 between the *apo*- and *holo*- forms in islets, and the consequent switch of intracellular partners, emerges from our dynamic
38 profiling data in which TAT-PeP5 was used to inhibit p75^{NTR}. This peptide blocks the ability of p75^{NTR} to interact with
39 intracellular partners, impairing the effect of its cycling between the *apo*- and *holo*- forms, thus releasing into the cytosol
40 its ICD partners and preventing the ICD-mediated recruitment of other effectors (Baeza-Raja et al., 2005), irrespective of
41 the availability of NGF in the extracellular environment. TAT-PeP5 treatment resulted in the loss of 50-60% of the insulin

secretory response of both mouse and human islets to glucose, providing evidence for a role of p75^{NTR} in the full amplitude of glucose-stimulated insulin secretion.

Effectors that are recruited by p75^{NTR}, including caveolin, small GTPases and their GDP dissociation inhibitors (GDI), have been implicated in β -cell secretory granule exocytosis (Bilderback et al., 1999; Muragaki et al., 1995; Wang and Thurmond, 2007). In particular, caveolin was identified as a CDC42-GDI in β -cells (Kowluru and Veluthakal, 2005), and p75^{NTR} is reported to bind both caveolin and Rho-GDI in PC12 pheochromocytoma cells through portions of its ICD domain (Yamashita and Tohyama, 2003; Bilderback et al., 1999). Our immunoprecipitation studies have now demonstrated physical interaction between p75^{NTR} and Rho-GDI in mouse β -cells, providing a basis for insulin granule movement in β -cells being downstream of p75^{NTR} bound to Rho-GDI. Our TAT-PeP5 experiments support this model, where blockade of the p75^{NTR} ICD would be expected to reduce glucose-stimulated granule translocation because of the impaired interaction between the receptor and Rho-GDI, and the data are consistent with p75^{NTR} cycling being important in delivering the correct amplitude of insulin secretion in response to a glucose challenge.

5. Conclusions.

The role of the autocrine NGF loop in islet β -cells goes beyond the canonical survival pathways promoted by this peptide. The NGF secretion profiling data, where there is a basal, tonic release and transient elevation following a glucose challenge, together with the insulin secretion data revealing that endogenous NGF inhibits basal insulin release while promoting glucose-stimulated insulin secretion suggest an autocrine role for NGF in the regulation of insulin secretion. We propose that NGF release allows fine-tuning of the β -cell secretory activity to regulate both basal insulin secretion and the appropriate biphasic profile of glucose-stimulated insulin secretion. The role played by p75^{NTR} at stimulatory concentrations of glucose is of particular interest as impairment of its cycling between the *apo* (NGF unbound) and *holo* (NGF bound) forms impacts severely on the secretory response to glucose, most likely through the inability of p75^{NTR} to recruit intracellular mediators controlling β -cell secretory granule movement.

Acknowledgements

We thank Dr. Beatriz Torío of the Department of Anatomical Pathology, University Hospital Complex of Palencia, Spain for providing human pancreas samples and verifying their non-pathological nature. We are also grateful to the families of donors for making available pancreases for isolation of the human islets used in this study.

Contribution statement

Experiments were designed by AP, MCC and SP, material was collected by RCC and GH and experiments were conducted by AP. Data were analysed by AP and SP and interpreted by AP, SP, GH, RCC, MCC and EC. AP and SP drafted the manuscript, and all authors have agreed to the final version of the manuscript.

Funding

This work was partially funded by the European Foundation for the Study of Diabetes (EFSD) via an Albert Renold Travel Grant to AP.

References

Amisten, S., Salehi, A., Rorsman, P., Jones, P.M., Persaud, S.J. 2013. An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans. *Pharmacology & Therapeutics* 139:359-91.

Baeza-Raja, B., Li, P., Le Moan, N., Sachs, B.D., Schachtrup, C., Davalos, D., Vagena, E., Bridges, D., Kim, C., Saltiel, A.R., Olefsky, J.M., Akassoglou, K., 2005. p75 neurotrophin receptor regulates glucose homeostasis and insulin sensitivity. *Proc Natl Acad Sci U S A* 102(15):5838-43.

Baeza-Raja, B., Sachs, B.D., Li, P., Christian, F., Vagena, E., Davalos, D., Le Moan, N., Ryu, J.K., Sikorski, S.L., Chan, J.P., Scadeng, M., Taylor, S.S., Houslay, M.D., Baillie, G.S., Saltiel, A.R., Olefsky, J.M., Akassoglou, K., 2016. p75 Neurotrophin Receptor Regulates Energy Balance in Obesity. *Cell Rep.* 14(2):255-68.

Bilderback, T.R., Gazula, V.R., Lisanti, M.P., Dobrowsky, R.T., 1999. Caveolin interacts with Trk A and p75(NTR) and regulates neurotrophin signaling pathways, *J Biol Chem*, 274(1):257-63.

Carito, V., Pingitore, A., Cione, E., Perrotta, I., Mancuso, D., Russo, A., Genchi, G., Caroleo, M.C., 2012. Localization of nerve growth factor (NGF) receptors in the mitochondrial compartment: characterization and putative role. *Biochim Biophys Acta* 1820(2):96-103.

Caroleo, M.C., Carito, V., Pingitore, A., Perrotta, I.D., Perri, M., Mancuso, D., Russo, A., Cione, E., 2015. Human kidney podocyte cell population as a novel biological target of nerve growth factor. *Growth Factors* 33(1):14-22.

Cohen, S., Levi-Montalcini, R., 1957. Purification and properties of a nerve growth-promoting factor isolated from mouse sarcoma 180. *Cancer Res.* 17 (1):15-20.

Deponti, D., Buono, R., Catanzaro, G., De Palma, C., Longhi, R., Meneveri, R., Bresolin, N., Bassi, M.T., Cossu, G., Clementi, E., Brunelli, S., 2009. The low-affinity receptor for neurotrophins p75NTR plays a key role for satellite cell function in muscle repair acting via RhoA. *Mol Biol Cell*;20(16):3620-7.

Freund, V, Frossard, N., 2004. Expression of nerve growth factor in the airways and its possible role in asthma *Prog Brain Res* 146:335-346.

Gey, G.O., Gey, M.K., 1936. The Maintenance of Human Normal Cells and Tumor Cells in Continuous Culture: I. Preliminary Report: Cultivation of Mesoblastic Tumors and Normal Tissue and Notes on Methods of Cultivation. *The American Journal of Cancer* 27: 45-76.

Gezginci-Oktayoglu, S., Bolkent, S., 2009. Exendin-4 exerts its effects through the NGF/p75NTR system in diabetic mouse pancreas. *Biochem Cell Biol* 87(4):641-51.

Hata, T., Sakata, N., Yoshimatsu, G., Tsuchiya, H., Fukase, M., Ishida, M., Aoki, T., Katayose, Y., Egawa, S., Unno, M., 2015. Nerve Growth Factor Improves Survival and Function of Transplanted Islets Via TrkA-mediated Cell Proliferation and Revascularization. *Transplantation.* 99(6):1132-43.

Hauge-Evans, A.C., Squires, P.E., Persaud, S.J., Jones, P.M., 1999. Pancreatic beta-cell-to-beta-cell interactions are required for integrated responses to nutrient stimuli: enhanced Ca²⁺ and insulin secretory responses of MIN6 pseudoislets. *Diabetes* 48(7):1402-8.

Huang, G.C., Zhao, M., Jones P., Persaud, S., Ramracheya, R., Lšbner, K., Christie, M.R., Banga, J.P., Peakman, M., Sirinivsan, P., Rela, M., Heaton, N., Amiel, S., 2004. The development of new density gradient media for purifying human islets and islet-quality assessments. *Transplantation* 77: 143-145.

Huber, L.J., Chao, M.V., 1995. A potential interaction of p75 and trkA NGF receptors revealed by affinity crosslinking and immunoprecipitation. *J Neurosci Res* 40:557-563.

Jones, P.M., Persaud, S.J., Howell, S.L., 1989. Time-course of Ca²⁺-induced insulin secretion from perfused, electrically permeabilised islets of Langerhans: effects of cAMP and a phorbol ester. *Biochem Biophys Res Commun* 162: 998-1003.

- 1
- 2 Jones, P.M., Salmon, D.M., Howell, S.L., 1988. Protein phosphorylation in electrically permeabilized islets of
- 3 Langerhans. Effects of Ca²⁺, cyclic AMP, a phorbol ester and noradrenaline. *The Biochemical journal* 254: 397-403.
- 4
- 5 Kaplan, D.R., Miller, F.D., 1997. Signal transduction by the neurotrophin receptors. *Curr Opin Cell Biol* 9:213-221.
- 6
- 7 Kim, H.C., Cho, Y.J., Ahn, C.W., Park, K.S., Kim, J.C., Nam, J.S., Im, Y.S., Lee, J.E., Lee, S.C., Lee, H.K., 2009.
- 8 Nerve Growth factor and expression of its receptor in patients with diabetic neuropathy. *Diabet Med.* 26(12):1228-34.
- 9
- 10 Kowluru, A., Veluthakal, R., 2005. Rho guanosine diphosphate-dissociation inhibitor plays a negative modulatory role
- 11 in glucose-stimulated insulin secretion. *Diabetes* 54: 3523-3529.
- 12
- 13 Larrieta, M.E., Vital, P., Mendoza-Rodriguez, A., Cerbon, M., Hiriart, M., 2006. Nerve growth factor increases in
- 14 pancreatic beta cells after streptozotocin-induced damage in rats. *Exp Biol Med (Maywood)* 231(4):396-402.
- 15
- 16 Liu, B., Asare-Anane, H., Al-Romaiyan, A., Huang, G., Amiel, S.A., Jones, P.M., Persaud, S.J., 2009. Characterisation
- 17 of the insulinotropic activity of an aqueous extract of *Gymnema sylvestre* in mouse beta-cells and human islets of
- 18 Langerhans. *Cell Physiol Biochem* 23(1-3):125-32
- 19
- 20 Muragaki, Y., Timothy, N., Leight, S., Hempstead, B.L., Chao, M.V., Trojanowski, J.Q., Lee, V.M., 1995. Expression
- 21 of trk receptors in the developing and adult human central and peripheral nervous system *J Comp Neurol* 356:387-397.
- 22
- 23 Nevins, A.K., Turmond D.C., 2006. Caveolin-1 functions as a novel Cdc42 guanine nucleotide dissociation inhibitor in
- 24 pancreatic beta-cells *J Biol Chem* 14;281(28):18961-7.
- 25
- 26 Niederhauser, O., Mangold, M., Schubnel, R., Kuszniir, E.A., Schmidt, D., Hertel, C., 2000. NGF ligand alters NGF
- 27 signaling via p75NTR and TrkA. *J Neurosci Res* 61 263.
- 28
- 29 Papadimitriou, A., King, A.J.F., Jones, P.M., Persaud, S.J. 2007. Anti-Apoptotic Effects of Arachidonic Acid and
- 30 Prostaglandin E2 in Pancreatic β -Cells. *Cell Physiol Biochem* 20:607-616.
- 31
- 32 Pierucci, D., Cicconi, S., Bonini, P., Ferrelli, F., Pastore, D., Matteucci, C., Marselli, L., Marchetti, P., Ris, F., Halban,
- 33 P., Oberholzer, J., Federici, M., Cozzolino, F., Lauro, R., Borboni, P., Marlier, L.N., 1991. NGF-withdrawal induces
- 34 apoptosis in pancreatic beta cells in vitro. *Diabetologia* 44(10):1281-95.
- 35
- 36 Rorsman, P., Renstrom, E., 2003. Insulin granule dynamics in pancreatic beta cells. *Diabetologia*;46(8):1029-45.
- 37
- 38 Rosenbaum, T., Vidaltamayo, R., Sánchez-Soto, M.C., Zentella, A., Hiriart, M. 1998. Pancreatic beta cells synthesize
- 39 and secrete nerve growth factor. *Proc Natl Acad Sci U S A* 95 (13):7784-8.
- 40
- 41 Rosenbaum, T., Sánchez-Soto, M.C., Hiriart, M., 2001. Nerve growth factor increases insulin secretion and barium
- 42 current in pancreatic beta-cells. *Diabetes* 50(8):1755-62.
- 43
- 44 Rosenbaum, T., Castañares, D.T., López-Valdés, H.E., Hiriart, M. 2002 Nerve growth factor increases L-type calcium
- 45 current in pancreatic beta cells in culture. *J Membr Biol.* 186(3):177-84.
- 46
- 47 Roux, P.P., Barker, P.A., 2002. Neurotrophin signaling through the p75 neurotrophin receptor. *Prog Neurobiol* 67:203-
- 48 233.
- 49
- 50 Sachs, B.D., Baillie, G.S., McCall, J.R., Passino, M.A., Schachtrup, C., Wallace, D.A., Dunlop, A.J., MacKenzie, K.F.,
- 51 Klusmann, E., Lynch, M.J., Sikorski, S.L., Nuriel, T., Tsigelny, I., Zhang, J., Houslay, M.D., Chao, M.V., Akassoglou,
- 52 K., 2007. p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a
- 53 PDE4/cAMP/PKA pathway. *J Cell Biol.* 18;177(6):1119-32.

- Suckale, J., Solimena, M., 2010. The insulin secretory granule as a signaling hub. *Trends Endocrinol Metab* 21 (10):599-609.
- Taborsky, G.J. Jr, Mei, Q., Bornfeldt, K.E., Hackney, D.J., Munding, T.O., 2014. The p75 neurotrophin receptor is required for the major loss of sympathetic nerves from islets under autoimmune attack. *Diabetes* 63(7):2369-79.
- Vidaltamayo, R., Sánchez-Soto, M.C., Hiriart, M. 2002 Nerve growth factor increases sodium channel expression in pancreatic beta cells: implications for insulin secretion. *FASEB J.* 16(8):891-2.
- Vidaltamayo, R., Mery, C.M., Angeles-Angeles, A., Robles-D'az, G., Hiriart, M., 2003. Expression of nerve growth factor in human pancreatic beta cells *Growth Factors* 21(3-4):103-7.
- Wang, Z., Oh, E., Thurmond, D.C., 2007. Glucose-stimulated Cdc42 signaling is essential for the second phase of insulin secretion. *J Biol Chem* 30;282(13):9536-46.
- Yamashita, T., Tohyama, M., 2003. The p75 receptor acts as a displacement factor that releases Rho from Rho-GDI. *Nat Neurosci* 6(5):461-7.
- Zampieri, N., Chao, M.V., 2006. Mechanisms of neurotrophin receptor signalling. *Biochem Soc Trans* 34 (Pt 4):607-11.

Figure Legends:

Figure 1: NGF and insulin secretion and expression in islets

a) Dynamic insulin and NGF secretion from 200 mouse islets was quantified using specific immunoassays. Results are expressed as fold increase over basal peptide release of 6 independent experiments (mean±SEM). b) Human pancreas sections were immunoprobed with antibodies directed against insulin (red) and NGF (green) and nuclei were stained with DAPI (blue). Islet cells in which insulin and NGF are co-localised are indicated by yellow fluorescence in the merged image. The image is representative of 3 independent human pancreas sections.

Figure 2: Effect of inhibition of endogenous NGF signaling on basal insulin secretion

Group of 3 mouse islets (a, d), 5 human islets (b, d) or 10 MIN6 pseudoislets (c) were incubated for one hour in the presence of the agents shown and insulin release was quantified by radioimmunoassay. Results are expressed as mean±SEM of 6 independent experiments in a) and c), and 3 independent experiments in b) and d), with 6-8 replicates per group. *p<0.05, **p<0.01, ***p<0.001 versus 2mM glucose. AbNGF: neutralising NGF antibody; Ro: Ro 08-2750; IgG: isotypic IgG.

Figure 3: Effect of blocking NGF binding to trkA and/or p75^{NTR} on insulin secretion

Groups of 40 mouse islets were perfused with buffers supplemented with 0.5µM Ro (a), 10µM Ro (b) or 50ng/mL NGF (c) and insulin secretion was quantified by radioimmunoassay. Area under the curve (AUC) data: t₀-t₇₀ full profile; t₀-t₃₀ 2mM glucose (basal); t₃₂-t₅₀ glucose-stimulated insulin secretion divided into first phase (t₃₂-t₄₀) and second phase (t₄₂-t₅₀); t₅₂-t₇₀ 2mM glucose (final). Data are expressed as mean±SEM of 4 separate groups of islets, representative of 4 independent experiments. In the perfusion profiles *p<0.05 and #p<0.01 vs the same time points of the controls, and in the AUC data *p<0.05 vs the same section of the control.

Figure 4: Impairment of NGF binding to trkA and/or p75^{NTR} reduces glucose-stimulated insulin secretion

Groups of 40 mouse islets were perfused with buffers supplemented with 2mM glucose in the absence (solid lines) or presence (dotted lines) of Ro. a) perfusion of mouse islets in the presence of 0.5μM and 10μM Ro at 2mM glucose. b) mouse islets were pre-exposed to 10μM Ro during the last 10 minutes of the pre-perfusion hour (dotted line) then challenged with 20mM glucose. Area under the curve (AUC) data: a) t₁₀-t₂₄ 0.5μM Ro; t₂₆-t₄₀ 10μM Ro; b) t₀-t₄₀ full profile; t₁₂-t₄₀ glucose-stimulated insulin secretion divided into first phase (t₁₂-t₂₈) and second phase (t₃₀-t₄₀). Data are expressed as mean±SEM of 6 separate groups of islets, representative of 2 independent experiments. In the perfusion profiles *p< 0.05, # p<0.01 vs the same time points of the controls and in the AUC data *p<0.05 and ** p<0.01 vs the same section of the control.

Figure 5: Effect of p75^{NTR} intracellular blockade on glucose-stimulated insulin secretion

Groups of 40 mouse islets (a) or 50 human islets (b) were pre-treated for 20 minutes in the absence or presence of 10μM TAT-PeP5 then perfused with buffers supplemented with the agents shown. Area under the curve (AUC) data: t₀-t₃₀ full profile; t₀-t₁₀ 2mM glucose (basal); t₁₂-t₃₀ glucose-stimulated insulin secretion; c) real time viability measurements of mouse islets (mean±SEM, n=10) in culture for 24h in the absence or presence of 10μM TAT-PeP5. Perfusion results are expressed as mean±SEM of 3-4 separate groups of islets, representative of 3 (human) or 4 (mouse) independent experiments. In the secretory profiles (a, b) and in c *p<0.05 and # p<0.01 vs the corresponding control data. In the AUC graphs, *p<0.05 and **p<0.01 vs the same section of the control.

Figure 6: p75^{NTR} interacts with Rho-GDI in MIN6 β-cells

The image shows immunoblotting for p75^{NTR} (upper panel, 75kDa) and Rho-GDI (lower panel, 21kDa) in protein extracts from MIN6 cell total lysate (TL) and immunoprecipitated (IP) Rho-GDI, and indicates that Rho-GDI binds to p75^{NTR}.